Back grey_arrow_rt.gif
China Approves Schering-Plough's Pegintron for Hepatitis B
  KENILWORTH, N.J., April 5 (UPI) -- Schering-Plough said Thursday the Chinese government approved Pegintron for the treatment of patients with chronic hepatitis B.
The approval, which came from the Chinese State Food and Drug Administration, makes Pegintron the only pegylated interferon in China indicated for a 24-week treatment course. Hepatitis B is the most prevalent infectious disease in China and one of the leading causes of death.
"Schering-Plough is pleased to offer this effective new treatment option for Chinese patients with chronic hepatitis B, a major public health problem in China," said Robert Spiegel, Schering-Plough's chief medical officer and senior vice president.
Approximately 120 million people are chronic carriers of the hepatitis B virus in China and more than 330,000 die from the disease annually.
  icon paper stack View Older Articles   Back to Top